Reuters Health: COVID vaccine proved safe, well tolerated in patients with rheumatic diseases
UC expert recommends further study differentiates between treatment, disease types
A new European study recently published in the Annals of Rheumatic Diseases shows that currently available COVID-19 vaccines rarely cause flares in patients with rheumatic and musculoskeletal disease. Flares were reported in less than 5% of all cases within the study.
While encouraging, Wenhai Shao, PhD, associate professor in the Division of Immunology, Allergy and Rheumatology in the University of Cincinnati's Department of Internal Medicine, told Reuters Health that further studies should differentiate whether patients are taking immunosuppressants or other types of drugs, compare to healthy individuals and note the severity of the rheumatic or musculoskeletal diseases when the vaccination was given for more specific results.
"A bioinformatics approach could be used to analyze the data in these different ways," Shao said.
Read the Reuters Health article.
Featured photo at top of vaccination courtesy of Shutterstock.com
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.